Amphastar Change In Cash Over Time
| AMPH Stock | USD 41.33 0.49 1.20% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Amphastar Performance and Amphastar Correlation. Amphastar |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amphastar. If investors know Amphastar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amphastar listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.14) | Earnings Share 3.01 | Revenue Per Share 14.942 | Quarterly Revenue Growth 0.059 | Return On Assets 0.0867 |
The market value of Amphastar P is measured differently than its book value, which is the value of Amphastar that is recorded on the company's balance sheet. Investors also form their own opinion of Amphastar's value that differs from its market value or its book value, called intrinsic value, which is Amphastar's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amphastar's market value can be influenced by many factors that don't directly affect Amphastar's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amphastar's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amphastar is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amphastar's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change In Cash Analysis
Compare Amphastar P and related stocks such as Collegium Pharmaceutical, Eagle Pharmaceuticals, and Alkermes Plc Change In Cash Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COLL | (4.4 M) | (4.4 M) | (4.4 M) | (4.4 M) | (5.9 M) | 94.1 M | 57.5 M | (34.5 M) | 27.8 M | 23.4 M | 6.6 M | 12.3 M | (12.7 M) | 63.8 M | 66.9 M |
| ALKS | 3.1 M | 45.2 M | 13.4 M | 70.6 M | 56.5 M | (43 M) | 5.3 M | 4.9 M | 75.5 M | (63 M) | 69.2 M | 64.6 M | (45.1 M) | 165 M | 173.2 M |
| EOLS | (187 K) | (187 K) | (187 K) | (187 K) | (187 K) | (187 K) | (187 K) | (187 K) | 93.2 M | 16.7 M | (7.3 M) | 43.7 M | (11.7 M) | 8.9 M | 12.7 M |
| NBIX | 4.9 M | (3.9 M) | 13.6 M | (19 M) | (13.8 M) | 43.2 M | 9.1 M | 171.4 M | (112 M) | (31.7 M) | 74.8 M | 153.7 M | (73.3 M) | (11.6 M) | (11 M) |
| IRWD | 16.4 M | 43 M | 49.4 M | (61.2 M) | (1.2 M) | 187 M | (207.3 M) | 71.7 M | 48.1 M | (1.6 M) | 185.5 M | 257.1 M | 36.1 M | (565.8 M) | (537.5 M) |
| ANIP | 1.1 M | 19.1 M | (22.4 M) | 11.1 M | 157.9 M | (14.4 M) | (127.3 M) | 3.8 M | 11.9 M | 19.3 M | (54.5 M) | 92.4 M | (52.1 M) | 167.9 M | 176.3 M |
| PBH | 38.5 M | 5.7 M | (3.3 M) | 12.7 M | (7 M) | 5.9 M | 14.6 M | (9.3 M) | (5 M) | 67.2 M | (62.5 M) | (5.1 M) | 31.3 M | (12 M) | (11.4 M) |
| PCRX | 5.1 M | 20 M | (36 M) | 2.4 M | 25 M | 19.5 M | (21 M) | 18.2 M | 78.4 M | (54.3 M) | 21.7 M | 485.6 M | (481.4 M) | 49.2 M | 51.6 M |
| PAHC | (620 K) | 5.3 M | (26.5 M) | (15.5 M) | 17.4 M | 4.4 M | 22.5 M | (26.9 M) | 28.4 M | (21.2 M) | 13.9 M | 24 M | (33 M) | 29.3 M | 30.8 M |
| EVO | (2.3 M) | (3.3 M) | 21.3 M | 6.6 M | 3.1 M | (4.2 M) | 39.4 M | (16.9 M) | 42 M | 168 M | 145.5 M | 276.7 M | (284.2 M) | 95.8 M | 100.5 M |
| SUPN | 878.6 K | 24.8 M | (8.2 M) | (7.3 M) | 3.4 M | (2.2 M) | 32.9 M | 33.9 M | 91.9 M | (10.9 M) | 107.3 M | (85.2 M) | (110.3 M) | (18.1 M) | (17.2 M) |
Amphastar P and related stocks such as Collegium Pharmaceutical, Eagle Pharmaceuticals, and Alkermes Plc Change In Cash description
My Equities
My Current Equities and Potential Positions
| Amphastar P | AMPH |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 41.33
Check out Amphastar Performance and Amphastar Correlation. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Amphastar technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.